| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0425 | Abt-418 | Agonist of neural nicotinic acetylcholine receptors |
|
| DCC0426 | Abt-472 | Novel PARP inhibitor |
|
| DCC0427 | Abt-546 Hydrochloride | Hghly selective antagonist for endothelin ET A receptor |
|
| DCC0428 | Abt-594 Tosylate | Potent nicotinic acetylcholine receptor agonist |
|
| DCC0429 | Abt-670 | Orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction |
|
| DCC0430 | Abt-925 | Selective dopamine D3 receptor antagonist |
|
| DCC0431 | Abtz-1 | Inhibitor of protein synthesis with potent activity against multidrug-resistant Gram-positive bacterial strains |
|
| DCC0432 | Abzi-1 | Novel agonist of STING (stimulator of interferon genes) with enhanced binding to STING and cellular function |
|
| DCC0433 | Ac[phe1,2,3,arg4,d-ala8]dynorphin A-(1–11)nh2 | Novel potent and selective KOR antagonist, potentially stabilizing the bioactive conformation and enhancing its metabolic stability |
|
| DCC0434 | Ac18az8 | Novel potent, nontoxic, and highly selective breast cancer resistance protein (BCRP) inhibitor |
|
| DCC0435 | Ac1nod4q | Novel blocker of HOX antisense intergenic RNA (HOTAIR) by abrogating the scaffold interaction with EZH2 |
|
| DCC0436 | ac-216 | Selective NPFF(1) receptor ligand |
|
| DCC0437 | Ac22(az8)2 | Novel potent, nontoxic, and highly selective breast cancer resistance protein (BCRP/ABCG2) inhibitor |
|
| DCC0438 | ac-260584 Oxalate | Orally bioavailable M(1) muscarinic receptor allosteric agonist improving cognitive performance in an animal model |
|
| DCC0439 | Ac2p20 | Novel inhibitor of Mycobacterium tuberculosis (Mtb) growth at acidic pH, killing Mtb by selectively depleting free thiols at acidic pH |
|
| DCC0440 | Ac2p36 | Novel inhibitor of Mycobacterium tuberculosis (Mtb), selectively killing Mtb at acidic pH and potentiating the bactericidal activity of isoniazid, clofazimine, and diamide |
|
| DCC0441 | Ac32az19 | Novel potent, nontoxic, and highly selective breast cancer resistance protein (BCRP) inhibitor |
|
| DCC0442 | Ac34fgalnaz | Prodrug of 4FGalNAz to label a variety of proteins in mammalian cells without perturbing endogenous glycosylation pathways and primarily act as a substrate for O-GlcNAc transferase (OGT) |
|
| DCC0443 | Ac36az9 | Novel potent, nontoxic, and highly selective breast cancer resistance protein (BCRP) inhibitor |
|
| DCC0444 | Ac-3933 | Novel benzodiazepine receptor partial inverse agonist |
|
| DCC0445 | Ac3az11 | Novel potent and selective multidrug resistance-associated protein 1 (MRP1, ABCC1) modulator |
|
| DCC0446 | Ac-430 | Novel potent and specific inhibitor of janus kinase 2 (JAK2) |
|
| DCC0447 | Ac4galnalk | Novel metabolic oligosaccharide engineering (MOE) reagent, being an efficient chemical tool to probe protein glycosylation |
|
| DCC0448 | Ac4glcnalk | Novel metabolic oligosaccharide engineering (MOE) reagent, being an efficient chemical tool to probe protein glycosylation |
|
| DCC0449 | Ac-5sglcnac | Novel, cell-permeable, potent O-GlcNAc transferase (OGT) inhibitor |
|
| DCC0450 | Ac-ats010-ke | Novel Selective, irreversible, and Rapid Cell-Permeable Inhibitor of Human Caspase-3 |
|
| DCC0451 | Acc1 Inhibitor 1q | Novel highly potent and selective acetyl-CoA carboxylase 1 (ACC1) inhibitor (hACC1: IC 50 =0.58nM, hACC2: IC 50 >10000nM) |
|
| DCC0452 | Acc2-in-2e | Novel Acetyl-CoA Carboxylase 2 (ACC2) Selective Inhibitor, Improving Whole-Body Insulin Resistance and Hyperglycemia in Diabetic Mice through Target-Dependent Pathways |
|
| DCC0453 | Acdala | Highly photodurable and blue-laser excitable fluorescent amino acid. acting as a highly fluorescent probe after being incorporated into specific positions of various antibodies, receptors, and enzymes |
|
| DCC0454 | Ac-devd-cho | Selective Caspase-3 inhibitor |
|
